vs
GERON CORP（GERN）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是GERON CORP的1.5倍（$69.8M vs $47.2M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -39.0%，领先423.1%），GERON CORP同比增速更快（67.1% vs 21.2%），过去两年GERON CORP的营收复合增速更高（1597.0% vs 53.7%）
杰龙公司是一家总部位于美国加利福尼亚州福斯特城的生物科技企业，专注于开发并商业化用于癌症治疗、可抑制端粒酶的治疗产品，深耕肿瘤治疗药物研发领域。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
GERN vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.5倍
$47.2M
营收增速更快
GERN
高出45.9%
21.2%
净利率更高
RIGL
高出423.1%
-39.0%
两年增速更快
GERN
近两年复合增速
53.7%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $47.2M | $69.8M |
| 净利润 | $-18.4M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | -29.4% | 33.2% |
| 净利率 | -39.0% | 384.0% |
| 营收同比 | 67.1% | 21.2% |
| 净利润同比 | 30.3% | 1769.2% |
| 每股收益（稀释后） | $-0.03 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GERNRIGL
| Q4 25 | — | $69.8M | ||
| Q3 25 | $47.2M | $69.5M | ||
| Q2 25 | $49.0M | $101.7M | ||
| Q1 25 | $39.6M | $53.3M | ||
| Q4 24 | — | $57.6M | ||
| Q3 24 | $28.3M | $55.3M | ||
| Q2 24 | $882.0K | $36.8M | ||
| Q1 24 | $304.0K | $29.5M |
净利润GERNRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $-18.4M | $27.9M | ||
| Q2 25 | $-16.4M | $59.6M | ||
| Q1 25 | $-19.8M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-26.4M | $12.4M | ||
| Q2 24 | $-67.4M | $-1.0M | ||
| Q1 24 | $-55.4M | $-8.2M |
毛利率GERNRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率GERNRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | -29.4% | 40.9% | ||
| Q2 25 | -25.4% | 60.1% | ||
| Q1 25 | -42.2% | 23.9% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | -99.8% | 25.4% | ||
| Q2 24 | -7860.9% | 1.2% | ||
| Q1 24 | -18465.1% | -23.6% |
净利率GERNRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | -39.0% | 40.2% | ||
| Q2 25 | -33.4% | 58.6% | ||
| Q1 25 | -50.1% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | -93.5% | 22.5% | ||
| Q2 24 | -7639.8% | -2.8% | ||
| Q1 24 | -18220.4% | -27.9% |
每股收益（稀释后）GERNRIGL
| Q4 25 | — | $14.11 | ||
| Q3 25 | $-0.03 | $1.46 | ||
| Q2 25 | $-0.02 | $3.28 | ||
| Q1 25 | $-0.03 | $0.63 | ||
| Q4 24 | — | $0.82 | ||
| Q3 24 | $-0.04 | $0.70 | ||
| Q2 24 | $-0.10 | $-0.06 | ||
| Q1 24 | $-0.09 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.1M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $248.7M | $391.5M |
| 总资产 | $567.4M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资GERNRIGL
| Q4 25 | — | $155.0M | ||
| Q3 25 | $78.1M | $137.1M | ||
| Q2 25 | $77.7M | $108.4M | ||
| Q1 25 | $83.7M | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | $60.3M | $61.1M | ||
| Q2 24 | $116.9M | $49.1M | ||
| Q1 24 | $189.8M | $49.5M |
总债务GERNRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益GERNRIGL
| Q4 25 | — | $391.5M | ||
| Q3 25 | $248.7M | $117.6M | ||
| Q2 25 | $259.5M | $81.9M | ||
| Q1 25 | $268.2M | $18.6M | ||
| Q4 24 | — | $3.3M | ||
| Q3 24 | $292.3M | $-14.6M | ||
| Q2 24 | $306.7M | $-29.9M | ||
| Q1 24 | $344.9M | $-31.7M |
总资产GERNRIGL
| Q4 25 | — | $513.6M | ||
| Q3 25 | $567.4M | $242.5M | ||
| Q2 25 | $555.2M | $206.7M | ||
| Q1 25 | $562.5M | $176.0M | ||
| Q4 24 | — | $164.0M | ||
| Q3 24 | $444.9M | $139.4M | ||
| Q2 24 | $449.4M | $128.4M | ||
| Q1 24 | $482.1M | $126.5M |
负债/权益比GERNRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.6M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GERNRIGL
| Q4 25 | — | $22.0M | ||
| Q3 25 | $-13.6M | $24.0M | ||
| Q2 25 | $-27.4M | $30.5M | ||
| Q1 25 | $-48.0M | $-893.0K | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | $-58.9M | $21.7M | ||
| Q2 24 | $-53.5M | $302.0K | ||
| Q1 24 | $-62.3M | $-5.0M |
自由现金流GERNRIGL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-53.7M | — | ||
| Q1 24 | $-62.9M | — |
自由现金流率GERNRIGL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6086.6% | — | ||
| Q1 24 | -20680.3% | — |
资本支出强度GERNRIGL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 23.4% | — | ||
| Q1 24 | 202.3% | — |
现金转化率GERNRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
